The Future of Sjögren's Treatments Seminar | Watch the Recording

The Future of Sjögren’s Treatments: A Patient Seminar on Emerging Therapies in Clinical Trials

Original Air Date: November 8, 2025

There’s real hope on the horizon for people living with Sjögren’s. Researchers and clinicians are making steady progress toward new therapies that could bring meaningful relief and many of these potential treatments are now in clinical trials. Whether you’re newly diagnosed or have been managing Sjögren’s for years, this seminar will help you better understand what’s ahead and how you can play a role in shaping the future of care.

In this recorded program, you’ll hear directly from leading experts in Sjögren’s research, patient care, and clinical trials. We walk through the basics of how clinical trials work, the different therapies currently being studied in the U.S., and what phase they’re in — including several trials the Foundation is actively connected with. You’ll also get a helpful overview of the immune system and learn how these new treatments are designed to target the disease at its source.

This session brings together everything you need to know about the latest Sjögren’s clinical trials — all in one place, from the trusted source you rely on for credible, up-to-date information.

Note: This information is current at the time of recording and is subject to change as new information becomes available.

Future of Sjögren's Treatments - Part 1
Session Handout Download

Part 1 of 4 of the 2025 Future of Sjögren's Treatments Seminar. Sjögren's Foundation President & CEO welcomes people to the seminar and gives an overview of the clinical trial process. She began with an overview on the basics of clinical trials and then specific requirements for Sjögren’s clinical trials. We presented the different trials in progress in the US for the companies that The Foundation is working with, including what phase these trials are in and if they are enrolling patients. We also included a basic primer on the immune system to help set the stage for our presentations on the mechanism of action given by our experts.

Future of Sjögren's Treatments - Part 2
Session Handout Download

Part 2 of 4 of The Future of Sjögren's Treatments Seminar. In this session, Sjögren’s expert, Dr. Ghaith Noaiseh dives into the first set of drugs and their mechanisms of action, meaning how they work in the body to hopefully bring Sjögren’s symptoms under control. Dr. Noaiseh covered the following therapies: Deucravacitinib sponsored by Bristol Myers Squibb, Dazodalibep sponsored by AMGEN, and Ianalumab sponsored by Novartis. Ianalamab is particularly interesting because the Phase 3 trial results showed success. We ended the session with a patient sharing their recent experience in Sjögren’s trials.

Future of Sjögren's Treatments - Part 3
Session Handout Download

Part 3 of 4 of The Future of Sjögren's Treatments Seminar. In the second of our two-part session on mechanisms of action, Sjögren’s expert Dr. Sara McCoy dives into additional therapies and how they work in the body to bring Sjögren’s symptoms under control. In this session, Dr. McCoy covered the following therapies: Nipocalimab by Johnson & Johnson/Janssen, Efgartigimod by argenx, HZN-1116 (now AMG 329) by AMGEN, Sibeprenlimab by Otsuka, and RSLV-132 by Resolve Therapeutics.

Future of Sjögren's Treatments - Part 4
Session Handout Download

Part 4 of 4 of The Future of Sjögren's Treatments. In this session, we discussed the emerging use of Car-T and T-Cell engager therapies. T cell therapy is a type of immunotherapy that shows the promise of resetting your immune system (for a period of time). There has been much excitement around this new treatment as it is showing great promise in many different diseases; however, it is extremely important to recognize what is involved and who this type of therapy is best suited for. Currently, there is no Car-T trial for Sjogren’s, but there is a Phase 1 trial for a T-cell engager called CLN-978 by Cullinan Therapeutics. Dr. Kapoor helped us understand these therapies, the differences between Car-T therapy and a T-cell engager therapy, and the potential use in Sjögren’s.